Tscan Therapeutics Inc (United States) is listed on the Nasdaq and has a market capitalization of $41.18 million, with shareholders equity totaling $69.02 million.
The company employs approximately 138 people and operates in the Others sector, within the Others industry.
Over the past 12 months, Tscan Therapeutics Inc reported $7.11 million in revenue, generating net income of $-117.71 million.
Key financial metrics include a P/E ratio of -0.35, a price-to-book (P/B) ratio of 0.60, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker TCRX.